One such context is discriminating between prostate cancer (PC) and benign prostatic hyperplasia (BPH), which may not be reliably accomplished using the measurement of serum prostate-specific antigen (PSA), resulting in many unnecessary biopsies [36]. The gene discussed is KLK3; the disease is benign prostatic hyperplasia.